/PRNewswire/ -- Azurity Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved XIFYRM™ (meloxicam injection), an IV non-steroidal anti-inflammatory drug (NSAID) that offers once daily dosing.

/PRNewswire/ -- Azurity Pharmaceuticals, Inc. 今天宣布，美国食品药品监督管理局 (FDA) 已批准 XIFYRM™（美洛昔康注射液），这是一种可每日一次给药的静脉注射非甾体抗炎药 (NSAID)。

XIFYRM is indicated for use in adults for the management of moderate-to-severe pain, alone or in combination with non-NSAID analgesics. XIFYRM provides a non-opioid analgesic in a 30mg/mL vial for IV bolus injection over 15 seconds. Because of delayed onset of analgesia, XIFYRM alone is not recommended for use when rapid onset of analgesia is required..

XIFYRM 适用于成人中度至重度疼痛的管理，可单独使用或与非甾体抗炎药（non-NSAID）类镇痛药联合使用。XIFYRM 提供一种非阿片类镇痛药，以 30mg/mL 的小瓶装供 15 秒内静脉推注。由于其镇痛作用起效较慢，因此当需要快速起效时，不建议单独使用 XIFYRM。

'XIFYRM demonstrates our commitment to improving patient care by providing an alternate dosage form for pain management,' said

“XIFYRM展示了我们通过提供一种替代的疼痛管理剂型来改善患者护理的承诺，”

Ron Scarboro

朗·斯卡伯勒

, CEO at Azurity Pharmaceuticals. 'XIFYRM addresses an important clinical need, especially for patients requiring a non-opioid component to multimodal analgesia strategies.'

，Azurity Pharmaceuticals首席执行官。“XIFYRM满足了重要的临床需求，特别是对于需要多模式镇痛策略中非阿片类成分的患者。”

XIFYRM will be available in the coming weeks. For full prescribing information, including boxed warning and safety profile, please visit

XIFYRM 将在未来几周内上市。如需完整的处方信息，包括黑框警告和安全特性，请访问

About Azurity Pharmaceuticals:

关于Azurity Pharmaceuticals：

Azurity Pharmaceuticals is a privately held company committed to delivering innovative, high-quality medicines for overlooked patients. Azurity's global footprint is over 50 countries, with a diversified portfolio of 30+ marketed brands spanning ten dosage forms and ten key therapeutic areas. Powered by its Next-Gen Commercial Model, Azurity leverages data, analytics, and AI-driven digital tools to enhance market reach and stakeholder engagement.

Azurity Pharmaceuticals 是一家致力于为被忽视的患者提供创新、高质量药物的私营公司。Azurity 的业务遍及 50 多个国家，拥有 30 多个上市品牌，涵盖十种剂型和十个关键治疗领域。通过其下一代商业模式，Azurity 利用数据、分析和人工智能驱动的数字工具来扩大市场覆盖范围并加强与利益相关者的互动。